Psoriasis, rheumatoid, atopic dermatitis, psoriasis, ankylosing spondylitis, ulcerative colitis, vitiligo

Baricent 2

• 2025-05-24

Drug Characteristics

• Generic Name: Baricitinib
• Drug Class: Oral small-molecule Janus kinase (JAK) inhibitor
• Primary Targets: JAK1 and JAK2

Key Features:

• Has immunomodulatory effects, controlling inflammation by blocking cytokine signaling pathways.
• First JAK inhibitor granted Emergency Use Authorization (EUA) by the FDA for severe COVID-19 treatment.
• Demonstrates efficacy in autoimmune diseases and virus-related inflammatory responses.

Indications:

Approved Indications:

Moderate-to-severe active rheumatoid arthritis (RA)

• For adults with inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

Severe Alopecia Areata (AA)

• Approved by the FDA in 2022; first systemic treatment approved for this condition.

Mechanism of Action

Baricitinib is a dual JAK1/JAK2 inhibitor. It works by blocking the JAK-STAT signaling pathway, thereby inhibiting multiple cytokine signals, including:

• IL-6
• IFN-γ
• GM-CSF
• And others

Therapeutic Effects:

• Suppresses overactivation of the immune system
• Reduces inflammation
• Minimizes immune-mediated tissue damage

Dosage and Administration

Global Market Overview:

• RA and alopecia markets are mature; Baricitinib competes with tofacitinib, upadacitinib, and other JAK inhibitors.
• Its global recognition rose significantly due to its role in COVID-19 management.
• Approved in China, US, EU, Japan, South Korea, and included in national healthcare systems and clinical guidelines.

Future Development Potential:

   Ongoing research for use in:

• Systemic Lupus Erythematosus (SLE)
• Atopic Dermatitis
• Psoriatic Arthritis
• Myositis

  Potential to expand into:

• Sjögren’s Syndrome
• Inflammatory Bowel Disease (IBD)
• Graft-versus-Host Disease (GVHD)